BR112012016856A2 - "método para produzir um derivado de pirrolidina 3,4-dissubstituído e produção de intermediários do mesmo." - Google Patents

"método para produzir um derivado de pirrolidina 3,4-dissubstituído e produção de intermediários do mesmo."

Info

Publication number
BR112012016856A2
BR112012016856A2 BRBR112012016856-8A BR112012016856A BR112012016856A2 BR 112012016856 A2 BR112012016856 A2 BR 112012016856A2 BR 112012016856 A BR112012016856 A BR 112012016856A BR 112012016856 A2 BR112012016856 A2 BR 112012016856A2
Authority
BR
Brazil
Prior art keywords
derivative
production
intermediates
producing
enantiometer
Prior art date
Application number
BRBR112012016856-8A
Other languages
English (en)
Inventor
Ichiro Araya
Kazuo Orita
Original Assignee
Kyorin Seiyaku Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyorin Seiyaku Kk filed Critical Kyorin Seiyaku Kk
Publication of BR112012016856A2 publication Critical patent/BR112012016856A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pyrrole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

Método para produzir um derivado de pirrolidina 3,4-dissubstituído e produção de intermediários do mesmo. A presente invenção refere-se a um método barato e industrialmente vantajoso para preparar (3r,4s)-3-(aminometil n-substituído)-4-fluoropirrolidina o uum enantiômetro da mesma que pode ser um intermediário para a produção de produtos farmacêuticos. A invenção refere-se a um método para preparar um derivado de (3r, 4s)-3-(ciclopropilaminometil n-substituído)-4-fluoropirrolidina ou é enantiômetro, ou seus sais, comprendendo uma etapa de fluoração de um derivado de 4-hidróxi-3-(aminometil n-substituído) pirrolidina representado pela fórmula geral (1) ou um enantiômetro do mesmo usando um derivado de tetrafluoreto de enxofre. Na fórmula (1), pg representa um grupo protetor para o grupo amino, e r1 representa um grupo c1 a c6 alquila que pode ser substítuido, ou um grupo c3 a c8 cicloalquila pode pode ser substituído.
BRBR112012016856-8A 2010-01-08 2011-01-07 "método para produzir um derivado de pirrolidina 3,4-dissubstituído e produção de intermediários do mesmo." BR112012016856A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2010002665 2010-01-08
PCT/JP2011/050206 WO2011083858A1 (ja) 2010-01-08 2011-01-07 ３，４－ジ置換ピロリジン誘導体の製造方法及び製造中間体

Publications (1)

Publication Number Publication Date
BR112012016856A2 true BR112012016856A2 (pt) 2015-09-01

Family

ID=44305593

Family Applications (1)

Application Number Title Priority Date Filing Date
BRBR112012016856-8A BR112012016856A2 (pt) 2010-01-08 2011-01-07 "método para produzir um derivado de pirrolidina 3,4-dissubstituído e produção de intermediários do mesmo."

Country Status (12)

Country Link
US (1) US20120283448A1 (pt)
EP (1) EP2524911A4 (pt)
JP (1) JPWO2011083858A1 (pt)
KR (1) KR20120112769A (pt)
CN (1) CN102695698A (pt)
AU (1) AU2011204131B2 (pt)
BR (1) BR112012016856A2 (pt)
CA (1) CA2786646A1 (pt)
MX (1) MX2012007934A (pt)
NZ (1) NZ601080A (pt)
SG (1) SG182370A1 (pt)
WO (1) WO2011083858A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115745953B (zh) * 2022-06-29 2024-06-11 上海凌凯医药科技有限公司 一种羟基氟代试剂及羟基氟代方法
CN115448896A (zh) * 2022-10-24 2022-12-09 江苏阿尔法药业股份有限公司 一种索非布韦中间体的制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU578793B2 (en) * 1985-02-15 1988-11-03 Dainippon Pharmaceutical Co. Ltd. Novel 1,8-naphthyridine derivatives and processes for preparation thereof
JPH0635458B2 (ja) * 1985-02-15 1994-05-11 大日本製薬株式会社 ピリドンカルボン酸誘導体、そのエステルおよびその塩
JPS61282382A (ja) * 1985-06-06 1986-12-12 Dainippon Pharmaceut Co Ltd フエニル置換１，８−ナフチリジン誘導体、そのエステルおよびその塩
WO2002083636A1 (fr) * 2001-04-06 2002-10-24 Eisai Co., Ltd. Derive de pyrolidine et son procede d'obtention
ATE443064T1 (de) * 2002-03-18 2009-10-15 Kyorin Seiyaku Kk 10-(3-cyclo propyl amino methyl-1-pyrrolidinyl) pyridobenzoxazin carbonsäure derivat mit wirkung gegen resistente bakterien
JP2007511597A (ja) * 2003-11-18 2007-05-10 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー 抗菌アミノキナゾリヂンヂオン誘導体
WO2006002047A2 (en) * 2004-06-15 2006-01-05 Glaxo Group Limited Antibacterial agents
US7667049B2 (en) * 2006-03-09 2010-02-23 Kyorin Pharmaceutical Co., Ltd. Process for producing 3,4-disubstituted pyrrolidine derivative and production intermediate thereof

Also Published As

Publication number Publication date
NZ601080A (en) 2014-03-28
JPWO2011083858A1 (ja) 2013-05-16
AU2011204131B2 (en) 2014-05-08
SG182370A1 (en) 2012-08-30
US20120283448A1 (en) 2012-11-08
AU2011204131A1 (en) 2012-07-26
WO2011083858A1 (ja) 2011-07-14
EP2524911A1 (en) 2012-11-21
KR20120112769A (ko) 2012-10-11
CA2786646A1 (en) 2011-07-14
EP2524911A4 (en) 2013-09-11
MX2012007934A (es) 2012-11-06
CN102695698A (zh) 2012-09-26

Similar Documents

Publication Publication Date Title
BR112014015363A2 (pt) derivados de ácido alfa-amino borônico, inibidores de imunoproteassoma seletivos
BR112014004219A2 (pt) pirano[3,2-d][1,3]tiazol como inibidores de glicosidase
BR112012006031A2 (pt) processo para preparação de compostos azabicíclicos.
BR112013011580A2 (pt) derivados de ácido bisfenil pentanoico substituído por amino como inibidores de nep
ECSP10010405A (es) Procesos e intermediarios para la preparacion de derivados de acido 5-bifenil-4-il-2-metilpentanoico
BR112012024403A2 (pt) processo de preparo de derivados de amino-benzofurano
BRPI0905147A8 (pt) processo para síntese de ivabradina e seus sais de adição com um ácido farmaceuticamente aceitável
AR051965A1 (es) Sales de la n-[2-( { (3r)-1-[trans-4-hidroxi-4-(6- metoxipiridin-3-il)-ciclohexil] pirrolidin-3- il} amino)-2- oxoetil]-3-(trifluormetil) benzamida
NO20090166L (no) Amino-imidazoloner og deres anvendelse som et medikament for behandling av kognitiv svekkelse, Alzheimers sykdom, neurodegenerering og demens
BRPI0812625A2 (pt) processo para preparar um sal de cis-atracúrio
BR112014026266A2 (pt) derivado de quinazolidinadiona
BR112014003079A2 (pt) derivado de 1,2,3,4-tetra-hidroquinolina útil para o tratamento de diabetes
BR112014000471A2 (pt) processo para preparo de derivados de diamida de ácido antranílico substituídos com tetrazol por meio da reação de ácidos pirazóis com ésteres antranílicos
EA201071238A1 (ru) Замещённое карбинольное соединение, содержащее циклический линкер
DE602006008962D1 (de) Verfahren zur herstellung von valsartan
CU24030B1 (es) Nuevos derivados de benzotiadiazepinas, su procedimiento de preparación y composiciones farmacéuticas que los contienen
BRPI0909560A2 (pt) processo de preparação de derivaods de ácido 1-(2-halo-bifenil-4-il)-ciclopropano carboxílico
BRPI1014802B8 (pt) profármacos de triptolida.
BR112018069712A2 (pt) composto ou um sal farmacologicamente aceitável do mesmo, composição farmacêutica, método para administração de uma quantidade eficaz de uma composição farmacêutica, e, inibidor de tnf-a.
AR075915A1 (es) Proceso para la obtencion de derivados de acido propionico
BRPI0516192A (pt) composto, e, método para a preparação de um composto
AR082881A1 (es) Proceso para preparar un derivado de piperidina, intermediario para sintetizar un medicamento
BR112012016856A2 (pt) "método para produzir um derivado de pirrolidina 3,4-dissubstituído e produção de intermediários do mesmo."
BR112014009390A2 (pt) corantes ácidos de trisazóicos
AR072776A1 (es) Procesos para la produccion de 2-amino-2-[2-(4-alquil c2-20-fenil)etil]propano-1,3-dioles y a compuestos intermediarios para usar con los mismos

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2342 DE 24-11-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.